Pharmacogenetics of Immunosuppressant Polymorphism of CYP3A5 in Renal Transplant Recipients

Transplantation Proceedings

Volumn 42, Issue 1, 2010, Pages 257-259

  Larriba, J ^a   Imperiali, N ^a   Groppa, R ^a   Giordani, C ^a   Algranatti, S ^a   Redal, M A ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; INFORMED CONSENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP3A; DNA; DNA PRIMERS; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 76749153280     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.11.028     Document Type: Article

References (19)

1. Burckart G.J. Pharmacogenomics: the key to improved drug therapy in transplant patients. Clin Lab Med 28 (2008) 411
2. Shiraga T., Matsuda H., Nagase K., et al. Metabolism of FK 506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog an human liver microsomes. Biochem Pharmacol 47 (1994) 727
3. Hebert M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27 (1997) 201
4. Saeki T., Ueda K., Tanigawara Y., et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268 (1993) 6077
5. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26 (2004) 192
6. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383
7. Lampen A., Christians U., Guengerich F.P., et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23 (1995) 1315
8. Thervet E., Anglicheau D., King B., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76 (2003) 1233
9. Hesselink D.A., van Schaik R.H., van der Heiden I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245
10. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p450 3A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486
11. Masuda S., Uemoto S., Hashida T., et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68 (2000) 98
12. Ferraresso M., Tirelli A., Ghio L., et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatric Transplant (2007) 11:296
13. Statistics Data Analysis (STATA) 8.0. http://www.stata.com Accessed August 2009
14. Girnita D.M., Webber S.A., Ferrell R., et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82 (2006) 1774
15. Saeki M., Saito Y., Nakamura T., et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in Japanese population. Hum Mutat 231 (2003) 653
16. Mourad M., Mourad G., Wallemacq P., et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80 (2005) 977
17. Yu S.F., Wu L.H., and Zheng S.S. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 5 (2006) 337
18. Zhao Y., Song M., Guan D., et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 37 (2005) 178
19. Tada H., Tsuchiya N., Satoh S., et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37 (2005) 1730